SBIR/STTR Research Award
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries
Award amount
$165,917Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Navidea Biopharmaceuticals, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- GQWFJQX2UKJ2
- Solicitation number
- PA13-234
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals (Navidea) is seeking SBIR FastTrack grant support to investigate the clinical utility, safety, and efficacy of its new product, 99mTc-tilmanocept, to identify sentinel lymph nodes (SLNs) during surgeries to remove early stage cervical cancers with the intent of improving patient outcomes and reducing post-surgical morbidities in patients undergoing these operations. Cancer patients can frequently be cured of their illnesses by surgeries that remove their tumors. To be successful, these surgeries must remove all of a patient's cancer. Residual tumor tissue in patients after surgery can result in potentially life threatening disease recurrences. It is very common that the first places to which a cancer may spread (metastasize) beyond the primary tumor are to lymph nodes that are immediately downstream from the tumor in the lymphatic flow, the SLNs. Previously and/or currently, it is/was standard of care in cervical cancer surgeries to remove e
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
- CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages
- CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages
- Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With mTc Tilmanocept
- mTc Tilmanocept for Targeting Rheumatoid Arthritis RA Driving Macrophages
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
16 SBIR/STTR records share this UEI (2012–2019). Reported award amounts total $13,069,016. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services